CurveBeam AI Accelerates Growth with Record Sales and New Financing Deal
CurveBeam AI reported a strong Q4 FY25 with record customer receipts and an 18% rise in purchase orders, while advancing key regulatory milestones and securing a major financing facility.
- Six purchase orders received in Q4 FY25 including two HiRise™ devices
- 18% increase in total purchase orders for FY25 compared to FY24
- Record quarterly receipts of A$5.6 million, up 72% year-on-year
- Positive cash flow from operations of A$0.4 million in Q4 FY25
- Near-finalisation of an A$18 million vendor financing facility to boost sales
Strong Sales Momentum
CurveBeam AI Limited (ASX, CVB) has delivered a robust finish to FY25, reporting six purchase orders in the final quarter, including two for its flagship HiRise™ CT scanners. This contributed to a total of 26 purchase orders for the full year, marking an 18% increase over FY24’s 22 orders. The company’s receipts from customers surged to a record A$5.6 million in Q4, a significant jump from A$1.5 million in the previous quarter and up 72% from the same period last year.
Improved Cash Flow and Operational Efficiency
Notably, CurveBeam AI turned its cash flow from operations positive in Q4 FY25, generating A$0.4 million compared to negative cash flows in prior quarters. This improvement was driven by reduced manufacturing costs and inventory management, alongside steady staff expenses. The company ended the quarter with A$5.0 million in cash and an additional A$5.0 million in receivables from previously secured purchase orders, providing a solid liquidity buffer as it moves forward.
Regulatory and Product Development Progress
On the product front, CurveBeam AI continues to advance validation of its enhanced HiRise™ scanner with a major robotic surgical system vendor. While the process remains internal to the vendor and timing uncertain, discussions have been constructive. Meanwhile, the company is progressing its bone mineral density (BMD) module, having completed 200 of 400 planned patient scans for comparative analysis with the established DXA method. The BMD module remains on track for FDA 510(k) clearance anticipated in the first half of calendar year 2026, a key milestone for broader market adoption.
Strategic Financing to Support Growth
CurveBeam AI is in the final stages of securing an A$18 million (€10 million) vendor financing facility with an international partner based in Switzerland. This facility will enable the company to offer leasing options to customers, particularly in North America and Europe, accelerating sales cycles and expanding market reach. The arrangement also allows immediate capitalisation of existing leased devices, expected to generate near-term positive cash inflows.
Looking Ahead
While Q1 FY26 is expected to see a modest increase in manufacturing costs due to supplier commitments and seasonal factors, CurveBeam AI anticipates some positive cash inflows from R&D tax incentives and other initiatives. The company remains focused on sales opportunities independent of the robotic surgery system validation, maintaining confidence in its qualified prospect pipeline.
Bottom Line?
CurveBeam AI’s strong finish to FY25 and strategic financing move set the stage for accelerated growth, but key regulatory and vendor validation milestones remain watchpoints.
Questions in the middle?
- When will the robotic surgical system vendor complete HiRise™ validation and what impact will it have on sales?
- Will the FDA 510(k) clearance for the BMD module be achieved on schedule in H1 CY26?
- How quickly will the new vendor financing facility translate into increased device sales and cash flow?
